NIU | Jotup

Niu Technologies Provides First Quarter 2024 Sales Volume Update

Retrieved on:

Thursday, April 4, 2024

In the first quarter of 2024, NIU sold 129,139 units, with 110,115 units sold in China market and 19,024 units sold in international markets.

Key Points:

In the first quarter of 2024, NIU sold 129,139 units, with 110,115 units sold in China market and 19,024 units sold in international markets.
In the domestic market, our new products have captured significant mindshare since their launch, collectively accounting for over 50% of the total sales volume in the first quarter.
In the international markets, our comprehensive product lineup and significant progress in retail channel expansion have driven our sales volume to 19,024 units.
Our sales volume count disclosed above is based on the delivery from our manufacturing facility, which may vary slightly from the sales volume measured from a financial accounting and reporting point of view.

Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million

Retrieved on:

Tuesday, April 2, 2024

We are also pleased to announce our authorized share repurchase program, and our agreed repurchase of all shares owned by Sumitomo Pharma.

Key Points:

We are also pleased to announce our authorized share repurchase program, and our agreed repurchase of all shares owned by Sumitomo Pharma.
The NEPTUNE study enrolled 26 subjects with active NIU who were randomized 2:1 to brepocitinib 45 mg once daily or brepocitinib 15 mg once daily.
All week 24 secondary efficacy endpoints, including haze grades, visual acuity, and macular thickness, were also positive and dose responsive.
The presentation and webcast details are also available under “Events & Presentations” in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events.

Niu Technologies to Report Fourth Quarter and Full Year 2023 Financial Results on Mar 18, 2024

Retrieved on:

Monday, February 19, 2024

NIU, PIN, Niu Technologies

BEIJING, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Niu Technologies (“NIU” or “the Company”) (NASDAQ: NIU), the world’s leading provider of smart urban mobility solutions, today announced that it will report its financial results for the fourth quarter and full year 2023 before the U.S. market opens on Monday, March 18, 2024.

Key Points:

BEIJING, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Niu Technologies (“NIU” or “the Company”) (NASDAQ: NIU), the world’s leading provider of smart urban mobility solutions, today announced that it will report its financial results for the fourth quarter and full year 2023 before the U.S. market opens on Monday, March 18, 2024.
The corporate presentation and financial spreadsheets will be posted on NIU’s investor relations website at:
The Company will host an earnings conference call on Monday, March 18, 2024 at 8:00 AM U.S. Eastern Time (8:00 PM Beijing/Hong Kong Time) to discuss the financial and business results.
To join via phone, participants need to register in advance of the conference call using the link provided below.
Upon registration, participants will receive dial-in numbers and a personal PIN, which will be used to join the conference call.

Everyone in Powersports Left Vegas a Winner

Retrieved on:

Thursday, February 29, 2024

"We're seeing all-time interest in dealer participation since our strategic decision to focus on the industry and go trade-only with the show.

Key Points:

"We're seeing all-time interest in dealer participation since our strategic decision to focus on the industry and go trade-only with the show.
And this year, we put on our best show yet — a direct result of the hard work, dedication, and tenacity of our team."
"On just the first day alone, we connected media with more than 10 OEMs launching new products.
Several electric-bike manufacturers also presented on the New Product Central stage, including Arctic Leopard USA, Denago Powersports, Greenger Powersports, JackRabbit Mobility, NIU, Rawrr eMoto, and Ryvid.

The macroeconomic effects of global supply chain reorientation

Retrieved on:

Saturday, February 10, 2024

Bank, Control, Quarterly Journal of Economics, Literature, Deutsche Bundesbank, Reconstruction, COVID-19, Monetary policy, Medical classification, Aggregate, Interest, Hail, Motion, Organization, WT, Policy, Smith, Elasticity, American Economic Review, Information, CHiPs, Journal of Economic Perspectives, Reproduction, Tagliapietra, Culture, Journal of International Economics, Section 3, European Commission, Communication, B16, Shock, NTM, European Chips Act, SSC, PHT, B17, Classification, Common, Tradability, Bank of Italy, Congressional Research Service, NT, Central bank, Private, Exercise, NIU, Labour, PDF, Website, European Parliament, Terrorism, Employment, B10, SUBST, Agricultural economics, F62, RTK, Bank of England, European Central Bank, Calibration, Agriculture, Foreign policy, Semiconductor, International Monetary Fund, Research Papers in Economics, Outline, Council, Openness, Bias, Economic system, European Council, Public policy, Deutsch, Statistics, GDP, Real, American Economic Journal, Table, Journal, YT, EAGLE, Household, Grossman, Science, Conference, Journal of Comparative Economics, Horse, SSRN, TC, Consumption, REA, F13, Section 2, University, Section 5, Legislation, Money, NTD, Central Bank of Ireland, Language, Capital, University of Limerick, Intermediate, CBI, Caselli, Macroeconomics, Crowding, Technical report, B14, Tax, Civil service commission, Growth, Commission, UNCTAD, Optimism, Politics, PIM, PX, Work, Social science, JEL, Government, Automation, HTT, Quarterly Journal, Canadian International Council, ECB, XT, METRO, ELAS, Credit, Bolt, Research, European Communities, American Journal, ArXiv, Unilateralism, Lerner, Motivation, International, C6, Committee, Security (finance)

We analyse the macroeconomic

Key Points:

We analyse the macroeconomic
effects of supply chain reorientation through localisation policies, using a global dynamic
general equilibrium model.
While arguments about comparative advantage, the potential forgone benefits of international specialisation and industry- and product-specific disruptions are familiar, there is less
analysis on the macroeconomic effects of supply chain changes resulting from localisation policies.
The large sensitivity of the global economy to the recent supply chain shocks suggests that
the international trade reconfiguration implied by localisation policies could also have sizable
impacts on key macroeconomic variables such as output, employment and inflation.
Thus, localisation focuses on the
goods in our model most closely related to global supply chains.
Retaliation also attenuates any positive effects from
reshoring on output and implies a reduction in the volume of overall international trade.
This finding calls for limiting the scope of reshoring, such as by focusing on vital goods that are
most susceptible to supply chain disruptions.
Either that, or the economic costs are considered a worthwhile trade-off for an increase
in security of supply, for example.
While arguments about comparative advantage, the potential forgone benefits of international specialisation and industry- and product-specific disruptions are familiar, there is less
analysis on the macroeconomic effects of supply chain changes resulting from localisation policies.
Recent supply chain shocks have had large effects, with disruptions in 2021 estimated
to have reduced euro area GDP by around two percent and doubled the rate of manufacturing producer inflation (Celasun et al., 2022).
To analyse this issue, we simulate a (partial) reshoring of production back to Europe in
a global dynamic general equilibrium framework.
Thus,
localisation focuses on the goods in our model most closely related to global supply chains.3 We
model reshoring through a direct change to the export goods? production-function parameters.
Since reshoring
effectively shortens the supply chain, the sum of markups along the chain falls.
This means that imports that are at the end of the supply chain (i.e.
In particular, our work relates to papers examining the potential for countries to reduce
their exposure to global supply chains.
(2021) demonstrate that reduced reliance on foreign inputs does not mitigate pandemicinduced contractions in labour supply.
(2021) find no evidence of a relationship
between global value chain integration and macroeconomic volatility.
This dynamic, along with factors such as natural disasters, climate-change
induced volatility and terrorism mean that supply chain disruptions could be a new normal
(Grossman et al., 2021).
Our work contributes to the literature providing dynamic general equilibrium analyses of
protectionist policies, in particular those using global macroeconomic models to quantify trade
policy changes.
(2008) analyse the effect of a rise in protectionism in response
to rising global trade imbalances.
Linde? and Pescatori (2019) find that although the macroeconomic costs of a
trade war are substantial, a fully symmetric retaliation is the best response.
(2020) consider a rich input-output structure and demonstrate that closer integration amplifies
the adverse effects of protectionist trade policies.
Several recent studies have also examined the economic effects of a global trade fragmentation.
First, we modify a dynamic general
equilibrium model of the global economy in order to analyse the transmission of localisation
policies.
This allows for a comprehensive treatment of cross-border macroeconomic interdependences and spillovers between the different regions.
4
There is, however, substantial cross-country heterogeneity in terms of impact, with small open economies
(SOEs) reliant on global supply chains more affected.
ECB Working Paper Series No 2903
7

Second, we are able to assess both long-run effects and the transition dynamics of localisation
policies.
Our model contains a detailed monetary block and captures inflation dynamics, which is a key
concern for supply chain reorientation.
Overall, our paper contains a careful analysis of the key aspects of the localisation debate,
including effects of localisation on domestic competition and efficiency.
Section 2 provides a brief overview of the model, the modifications to examine
global supply chain reorientation, some key details on the calibration and a brief discussion of
the nature of our exercise.
(2020) for discussions of the relative strengths and weaknesses of
trade and macroeconomic models in assessing large economic shocks.
2.1
Supply chain reorientation

Our analysis focuses on imported inputs used to produce goods for export, as the introduction
of localisation policies is in response to recent disruptions to global supply chains.
Since reshoring
effectively shortens the supply chain, the sum of markups along the chain falls.
Further to
these effects, engagement with global firms provides an opportunity for knowledge spillovers to
local firms (Criscuolo et al., 2017).
This finding calls for limiting the scope of reshoring, such as by focusing on vital goods that are
most susceptible to supply chain disruptions.
(B12)
Adjusting the share of local inputs in export goods, of course, affects prices and quantities all
along the supply chain.

Niu Technologies Provides Fourth Quarter and Full Year 2023 Sales Volume Update

Retrieved on:

Saturday, January 6, 2024

NIU, Growth, Best Buy, Media Markt

In the fourth quarter of 2023, NIU sold 137,476 units, including e-motorcycles, e-mopeds, e-bicycles, kick-scooters and e-bikes.

Key Points:

In the fourth quarter of 2023, NIU sold 137,476 units, including e-motorcycles, e-mopeds, e-bicycles, kick-scooters and e-bikes.
The macro environment in China, which has been recovering at a relatively slow pace, along with the usual cyclical fourth-quarter weakness, acted as a drag on NIU’s domestic sales volume.
Our offline retail sales exceeded 80% of the total micro-mobility sales volume, marking a significant increase from the 46% a year ago.
Our sales volume count disclosed above is based on the delivery from our manufacturing facility, which may vary slightly from the sales volume measured from a financial accounting and reporting point of view.

Alimera Completes Recruitment for the Synchronicity Study

Retrieved on:

Thursday, January 4, 2024

Alimera Sciences, Fluocinolone acetonide, Physician, Acquisition, Inflammation, NIU, Patient, Safety, Retina, Pharmaceutical industry

ATLANTA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces that it has completed enrollment for the company’s Synchronicity Study, a prospective, open-label clinical study evaluating the safety and efficacy of YUTIQ (fluocinolone acetonide intravitreal implant 0.18mg) in the treatment of chronic non-infectious uveitis and related intraocular inflammation.

Key Points:

ATLANTA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces that it has completed enrollment for the company’s Synchronicity Study, a prospective, open-label clinical study evaluating the safety and efficacy of YUTIQ (fluocinolone acetonide intravitreal implant 0.18mg) in the treatment of chronic non-infectious uveitis and related intraocular inflammation.
“We are pleased to reach the enrollment target for this Phase 4 open-label study only a few short months after our acquisition of YUTIQ,” said Rick Eiswirth, Alimera’s President and Chief Executive Officer.
“We look forward to the initial readout from this study in the second half of next year to provide retina specialists with a broader sense of the utility of fluocinolone acetonide in a durable intravitreal implant across a variety of patients with chronic non-infectious uveitis affecting the posterior segment (NIU-PS).
This could potentially benefit both YUTIQ in the United States and ILUVIEN in Europe and the Middle East, where it is approved to treat chronic NIU-PS.”

Niu Technologies Announces Appointment of New Director of the Board of Directors

Retrieved on:

Friday, December 22, 2023

HEC Paris, CFO, American Institute, Niu Technologies, Viadeo, Financial management, Artificial intelligence, Alibaba Group, Certified Public Accountant, NIU, SOGO, Economics, Management

BEIJING, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Niu Technologies (“NIU”, or “the Company”) (NASDAQ: NIU), the world’s leading provider of smart urban mobility solutions, today announces that the Company has appointed Ms. Fion Wenjuan Zhou as a new director of the board of directors of the Company (the “Board”), effective from December 25, 2023.

Key Points:

BEIJING, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Niu Technologies (“NIU”, or “the Company”) (NASDAQ: NIU), the world’s leading provider of smart urban mobility solutions, today announces that the Company has appointed Ms. Fion Wenjuan Zhou as a new director of the board of directors of the Company (the “Board”), effective from December 25, 2023.
Ms. Fion Zhou has served as the chief financial officer of the Company since November 2021, and she was awarded “Female CFO of the Year” by the Barron’s China in 2022.
Prior to that, she also held senior finance roles at Viadeo S.A. in Paris and Concord Medical Services Holdings Limited in New York City.
Ms. Zhou is a member of the American Institute of Certified Public Accountants and a Chartered Global Management Accountant.

Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus

Retrieved on:

Monday, November 27, 2023

Dermatomyositis, Uveitis, Hidradenitis suppurativa, Caregiver, Alopecia areata, SLE, Lupus, Calendar, NIU, Patient, Safety, Psoriasis, Ulcerative colitis, Pharmaceutical industry

Priovant plans to disclose the study data at a future date.

Key Points:

Priovant plans to disclose the study data at a future date.
“We saw some of the highest SRI-4 responder rates ever observed in a lupus study in the active arm of this trial, along with a favorable safety and tolerability profile.
Unfortunately, we also saw the highest placebo response rate observed in any significant SLE study, and as such it was not possible to truly assess the impact of the drug, or to establish sufficient differentiation from other therapies in lupus patients.
Oral brepocitinib has demonstrated statistically significant clinically meaningful benefit in six completed placebo-controlled Phase 2 studies in psoriasis, psoriatic arthritis, alopecia areata, hidradenitis suppurativa, ulcerative colitis, and Crohn’s disease.

Niu Technologies Announces Third Quarter 2023 Financial Results

Retrieved on:

Monday, November 20, 2023

Advertising, NIU, Marketing, Investment, RMB, Research, PIN, Video game

BEIJING, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Niu Technologies (“NIU”, or “the Company”) (NASDAQ: NIU), the world’s leading provider of smart urban mobility solutions, today announced its financial results for the third quarter ended September 30, 2023.

Key Points:

Accessories, spare parts sales and services revenues were RMB 94.4 million, a decrease of 4.5% and represented 10.2% of total revenues.
Net loss was RMB 79.4 million, compared with net income of RMB 2.9 million in the third quarter of 2022.
NIU expects revenues of the fourth quarter 2023 to be in the range of RMB 490 million to RMB 612 million, representing a year-over-year decrease of 20% to 0%.
The Company will host an earnings conference call on Monday, November 20, 2023 at 8:00 AM U.S. Eastern Time (9:00 PM Beijing/Hong Kong Time) to discuss its third quarter 2023 financial and business results and provide a corporate update.